Analyzing Teva Pharmaceutical Indus’s Unusual Options Activity
On Friday, shares of Teva Pharmaceutical Indus (NYSE:TEVA) saw unusual options activity. After the option alert, the stock price moved down to $8.84.
Understanding Teva Pharmaceutical Indus’s Unusual Options Activity
Shares of Teva Pharmaceutical Indus (NYSE:TEVA) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved up to $8.98.
Understanding Teva Pharmaceutical Indus’s Unusual Options Activity
Teva Pharmaceutical Indus (NYSE:TEVA) shares experienced unusual options activity on Tuesday. The stock price moved up to $8.71 following the option alert.
Unusual Options Activity Insight: Teva Pharmaceutical Indus
On Monday, shares of Teva Pharmaceutical Indus (NYSE:TEVA) saw unusual options activity. After the option alert, the stock price moved down to $8.38.
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Monday
Monday morning, 285 companies reached new 52-week lows.
Teva Recalls One Batch Of Topotecan After Complaint Of Glass Particulate In Vial
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is recalling one lot of its cancer drug topotecan injection after a pharmacy complaint flagged the presence of a single glass particulate in a vial of the drug.
New York Takes Drugmakers, Drug Retailers To Legal Trial Over Opioid
Teva Pharmaceutical Industries Ltd (NYSE:TEVA), Endo International Plc (NASDAQ:ENDP), and AbbVie Inc’s (NYSE:ABBV) Allergan misleadingly marketed opioid drugs as having a low addiction risk, a…
JNJ’s $260M Settlement Could Serve As Global Opioid Deal Template: Analyst
Over the weekend, Johnson & Johnson (NYSE: JNJ) reached a major opioid litigation settlement that could have broader implications for the biopharmaceutical industry.
Teva And Bioeq Announce Commercial Partnership For FYB201; Financial Terms Not Disclosed
Agreement includes commercializing biosimilar candidate of ophthalmology drug ranibizumab (Lucentis®) in Europe, Canada, Israel and global markets
Teva Pharmaceutical Industries Ltd. (NYSE:AND) and Bioeq AG
Johnson & Johnson Reaches $230M Settlement With New York State To End Sale Of Opioids Nationwide
On Saturday, Johnson & Johnson (NYSE: JNJ) said it would end the manufacture and sale of opioids nationwide in a $230 million settlement with the New York state,